Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a simple protein infusion save more lives from septic shock?

NCT ID NCT05148286

Recruiting now Disease control Sponsor: Asan Medical Center Source: ClinicalTrials.gov ↗

First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This trial investigates whether giving the protein albumin together with standard intravenous fluids during the first hours of treatment can reduce deaths in people with septic shock. About 2,400 adults arriving at emergency departments with septic shock will be randomly assigned to receive either albumin plus crystalloid fluids or crystalloid fluids alone. The main goal is to see if adding albumin lowers the chance of dying within 28 days.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a combination of 20% human albumin and crystalloid fluids given intravenously
What this could lead to
If it works, this could establish a simple, widely available addition to initial fluid therapy that reduces deaths from septic shock.
What could go wrong
This is a single open-label trial; prior studies have shown mixed results for albumin in sepsis, and the benefit may be modest or absent.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SEPTIC SHOCK are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

toxic shock syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SEPTIC SHOCK

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Email: •••••@•••••

Locations

  • Asan Medical Center

    RECRUITING

    Seoul, 05505, South Korea

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.